Terms: = Colorectal cancer AND FBXO11, MGC44383, 80204, ENSG00000138081, Q86XK2, VIT1, UG063H01, PRMT9, FLJ12673, FBX11
4 results:
1. Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic colorectal cancer.
Kimura M; Usami E; Teramachi H; Yoshimura T
Anticancer Res; 2021 Jun; 41(6):3091-3097. PubMed ID: 34083302
[TBL] [Abstract] [Full Text] [Related]
2. The tumor suppressive miR-26a regulation of fbxo11 inhibits proliferation, migration and invasion of hepatocellular carcinoma cells.
Ma Y; Deng F; Li P; Chen G; Tao Y; Wang H
Biomed Pharmacother; 2018 May; 101():648-655. PubMed ID: 29518611
[TBL] [Abstract] [Full Text] [Related]
3. F-box protein 11 promotes the growth and metastasis of gastric cancer via PI3K/AKT pathway-mediated EMT.
Sun C; Tao Y; Gao Y; Xia Y; Liu Y; Wang G; Gu Y
Biomed Pharmacother; 2018 Feb; 98():416-423. PubMed ID: 29278851
[TBL] [Abstract] [Full Text] [Related]
4. Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome.
Salo-Mullen EE; Lynn PB; Wang L; Walsh M; Gopalan A; Shia J; Tran C; Man FY; McBride S; Schattner M; Zhang L; Weiser MR; Stadler ZK
Fam Cancer; 2018 Jan; 17(1):71-77. PubMed ID: 28555354
[TBL] [Abstract] [Full Text] [Related]
